leadf
logo-loader
viewBetterLife Pharma Inc

BetterLife Pharma forms psychedelic research advisory board and taps industry veteran Hattie Wells as its first member

Wells brings over 20 years of experience in the psychedelics space, working with molecules and looking at the therapeutic benefits for mental health disorders

Mushrooms overlayed by chemical composition diagram
BetterLife is focused on the development and commercialization of next generation psychedelic products for the treatment of mental disorders

BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) tapped the experience of psychedelic pioneer Hattie Wells to join its new psychedelic research advisory board.

The Vancouver-based firm is forming the Next Generation Psychedelic Research Advisory Board with Wells as its first member, according to a statement Thursday.

Wells brings over 20 years of experience in the psychedelics space, working with molecules and looking at the therapeutic benefits for mental health disorders. Her research appeared in the Multidisciplinary Association for Psychedelic Studies and she currently serves as co-director of Breaking Convention, Europe’s largest conference on psychedelic consciousness.

READ: BetterLife Pharma seeks patent protection for new 2-Bromo-LSD formulations to treat depression and mood disorders

Wells has worked with Amnesty International, Transform Drug Policy Foundation, The International Center for Ethnobotanical Education, Research, and Service (ICEERS), the Global Diversity Foundation, and The Joint Nature Conservation Committee and Centre for Biocultural Diversity. She holds an MSc in Ethnobotany from the University of Kent, and BSc in Social Anthropology from The London School of Economics.

“We welcome Hattie Wells to advise and assist our team in developing the next generation psychedelic products,” BetterLife CEO Ahmad Doroudian said in a statement.

“Her more than 20 years of experience in this field is a great addition to our clinical and regulatory team as we continue to advance our plans in developing our products to treat mental health disorders and become the leader in the psychedelic space.”

BetterLife is focused on the development and commercialization of next generation psychedelic products for the treatment of mental disorders.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: BetterLife Pharma Inc

Price: 0.8871 USD

OTCQB:BETRF
Market: OTCQB
Market Cap: $44.66 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BetterLife Pharma Inc named herein, including the promotion by the Company of BetterLife Pharma Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

BetterLife Pharma reveals clinical trial updates on its treatment for...

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) CEO Ahmad Doroudian updates Proactive on the group's clinical trials progress, revealing it has engaged the clinical research organization Pharmaceutical Solutions Ltd to manage its study of AP-003 as a treatment for mild-to-moderate...

on 10/16/2020

2 min read